JPWO2021226348A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021226348A5 JPWO2021226348A5 JP2022567321A JP2022567321A JPWO2021226348A5 JP WO2021226348 A5 JPWO2021226348 A5 JP WO2021226348A5 JP 2022567321 A JP2022567321 A JP 2022567321A JP 2022567321 A JP2022567321 A JP 2022567321A JP WO2021226348 A5 JPWO2021226348 A5 JP WO2021226348A5
- Authority
- JP
- Japan
- Prior art keywords
- ndv
- protein
- transgene
- recombinant
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 170
- 108700019146 Transgenes Proteins 0.000 claims description 85
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 82
- 239000002773 nucleotide Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 44
- 125000000539 amino acid group Chemical group 0.000 claims description 35
- 238000013518 transcription Methods 0.000 claims description 34
- 230000035897 transcription Effects 0.000 claims description 34
- 230000001086 cytosolic effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 229940096437 Protein S Drugs 0.000 claims description 14
- 101710198474 Spike protein Proteins 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 235000004279 alanine Nutrition 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 230000007017 scission Effects 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 210000002845 virion Anatomy 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 claims description 4
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 101150084044 P gene Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000000991 chicken egg Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021677P | 2020-05-07 | 2020-05-07 | |
| US63/021,677 | 2020-05-07 | ||
| US202063051858P | 2020-07-14 | 2020-07-14 | |
| US63/051,858 | 2020-07-14 | ||
| US202063057267P | 2020-07-27 | 2020-07-27 | |
| US63/057,267 | 2020-07-27 | ||
| US202063058435P | 2020-07-29 | 2020-07-29 | |
| US63/058,435 | 2020-07-29 | ||
| US202063059924P | 2020-07-31 | 2020-07-31 | |
| US63/059,924 | 2020-07-31 | ||
| PCT/US2021/022848 WO2021194826A2 (en) | 2020-03-24 | 2021-03-17 | Recombinant sars-cov-2 spike protein and uses thereof |
| USPCT/US2021/022848 | 2021-03-17 | ||
| PCT/US2021/031110 WO2021226348A2 (en) | 2020-05-07 | 2021-05-06 | Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524990A JP2023524990A (ja) | 2023-06-14 |
| JP2023524990A5 JP2023524990A5 (https=) | 2024-05-29 |
| JPWO2021226348A5 true JPWO2021226348A5 (https=) | 2024-05-29 |
Family
ID=78468787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567321A Pending JP2023524990A (ja) | 2020-05-07 | 2021-05-06 | ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230310583A1 (https=) |
| EP (1) | EP4146674A4 (https=) |
| JP (1) | JP2023524990A (https=) |
| BR (1) | BR112022022604A2 (https=) |
| CA (1) | CA3178875A1 (https=) |
| MX (1) | MX2022013934A (https=) |
| WO (1) | WO2021226348A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021229270A1 (es) * | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| CN113881704B (zh) * | 2021-11-17 | 2024-02-13 | 浙江迪福润丝生物科技有限公司 | 一种包含新型冠状病毒双抗原靶标序列组合的重组新城疫病毒载体及相应疫苗株和疫苗 |
| CN114196701B (zh) * | 2021-11-17 | 2023-10-10 | 浙江迪福润丝生物科技有限公司 | 一种sars-cov-2的二价重组新城疫病毒载体及相应疫苗株和制备方法 |
| CN117247463A (zh) * | 2021-12-16 | 2023-12-19 | 浙江迪福润丝生物科技有限公司 | 一种展示新冠病毒s蛋白的融合蛋白和重组病毒粒子及其应用 |
| KR20240137110A (ko) * | 2022-02-02 | 2024-09-19 | 워싱턴 유니버시티 | 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법 |
| JP2025509352A (ja) * | 2022-03-10 | 2025-04-11 | アイカーン スクール オブ メディスン アット マウント サイナイ | Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物 |
| US20250228929A1 (en) * | 2022-04-03 | 2025-07-17 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant |
| WO2024174012A1 (pt) * | 2023-02-24 | 2024-08-29 | Instituto Butantan | Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101492643B1 (ko) * | 2005-12-02 | 2015-02-12 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도 |
| MX2019011599A (es) * | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
| US20190382450A1 (en) * | 2018-06-18 | 2019-12-19 | University Of Maryland, College Park | Newcastle disease virus-based vectored vaccine |
-
2021
- 2021-05-06 MX MX2022013934A patent/MX2022013934A/es unknown
- 2021-05-06 BR BR112022022604A patent/BR112022022604A2/pt unknown
- 2021-05-06 JP JP2022567321A patent/JP2023524990A/ja active Pending
- 2021-05-06 EP EP21800838.1A patent/EP4146674A4/en active Pending
- 2021-05-06 CA CA3178875A patent/CA3178875A1/en active Pending
- 2021-05-06 US US17/922,777 patent/US20230310583A1/en active Pending
- 2021-05-06 WO PCT/US2021/031110 patent/WO2021226348A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7212198B2 (ja) | Ｒｓｖ ｆタンパク質突然変異体 | |
| Yao et al. | Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces | |
| AU2017203189B2 (en) | Expression systems | |
| KR101153929B1 (ko) | 기능성 인플루엔자 바이러스 유사입자 | |
| JP2023513502A (ja) | コロナウイルスワクチン | |
| JP2023513913A (ja) | 麻疹ベクターを用いたｃｏｖｉｄ－１９免疫原性組成物及びワクチン | |
| CN104962581B (zh) | 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株 | |
| US10098943B2 (en) | Flavivirus virus like particle | |
| JP2012110339A (ja) | 欠陥インフルエンザウイルス粒子 | |
| Otsuki et al. | Canine distemper virus with the intact C protein has the potential to replicate in human epithelial cells by using human nectin4 as a receptor | |
| CA2673373A1 (en) | Rsv f-protein and its use | |
| US20200109176A1 (en) | Compositions And Methods For Making And Using Virus-Like Particles (VLPs) | |
| JPWO2021226348A5 (https=) | ||
| US20250228929A1 (en) | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant | |
| TW202012629A (zh) | 嵌合載體 | |
| WO2023109979A2 (zh) | 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用 | |
| CN119431524A (zh) | Rsv融合前构象f蛋白的突变体及其应用 | |
| JP2013502217A5 (https=) | ||
| RU2813150C2 (ru) | Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа | |
| CA3112040C (en) | Compositions and methods for making and using virus-like particles (vlps) | |
| JP2026000534A (ja) | 変異型ｓｌａｍタンパク質又はその活性断片 | |
| TW202306968A (zh) | 用於誘導對流感病毒的特異性免疫和／或預防流感病毒相關疾病的基於流感病毒的分離重組病毒 | |
| JP2024503482A (ja) | 複製可能アデノウイルス４型ｓａｒｓ－ｃｏｖ－２ワクチンおよびそれらの使用 | |
| OA21734A (en) | Influenza virus-based isolated recombinant virus. | |
| CN120718119A (zh) | 基于结构设计的稳定于融合前构象的rsv-f蛋白突变体 |